Advanced search
Publication Cover
Emerging Microbes & Infections Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,547
Views
0
CrossRef citations to date
0
Altmetric
Coronaviruses

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection

Rea Bingulaa UMR UNH, ECREIN, Immunology Laboratory, Faculty of Medicine, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
,
Hélène Chabrollesb Virology Department, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), 3IHP, Clermont-Ferrand, France;c CNRS UMR 6023, LMGE, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
,
Benjamin Bonneta UMR UNH, ECREIN, Immunology Laboratory, Faculty of Medicine, Clermont Auvergne University, Clermont-Ferrand, France;d Immunology Department, Clermont-Ferrand University Hospital (CHU Clermont Ferrand), Clermont-Ferrand, FranceView further author information
,
Christine Archimbaudb Virology Department, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), 3IHP, Clermont-Ferrand, France;c CNRS UMR 6023, LMGE, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
,
Amélie Brebionb Virology Department, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), 3IHP, Clermont-Ferrand, FranceView further author information
,
Justine Cosmed Immunology Department, Clermont-Ferrand University Hospital (CHU Clermont Ferrand), Clermont-Ferrand, FranceView further author information
,
Amandine Olliere Clinical Research and Innovation Direction, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand) 3 IHP, Clermont-Ferrand, FranceView further author information
,
Frédéric Dutheilf Preventive and Occupational Medicine, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), Clermont-Ferrand, France;g CNRS, LaPSCo Physiological and Psychosocial Stress, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
,
Maud Jundad Immunology Department, Clermont-Ferrand University Hospital (CHU Clermont Ferrand), Clermont-Ferrand, FranceView further author information
,
Audrey Mirandb Virology Department, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), 3IHP, Clermont-Ferrand, France;c CNRS UMR 6023, LMGE, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
,
Christel Regagnonb Virology Department, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), 3IHP, Clermont-Ferrand, France;c CNRS UMR 6023, LMGE, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
,
Magali Vidalb Virology Department, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), 3IHP, Clermont-Ferrand, France;c CNRS UMR 6023, LMGE, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
,
Cécile Henquellb Virology Department, Clermont-Ferrand University Hospital (CHU Clermont-Ferrand), 3IHP, Clermont-Ferrand, France;c CNRS UMR 6023, LMGE, Clermont Auvergne University, Clermont-Ferrand, FranceView further author information
&
Bertrand Evrarda UMR UNH, ECREIN, Immunology Laboratory, Faculty of Medicine, Clermont Auvergne University, Clermont-Ferrand, France;d Immunology Department, Clermont-Ferrand University Hospital (CHU Clermont Ferrand), Clermont-Ferrand, FranceCorrespondence[email protected]
View further author information
 show all
Article: 2184176 | Received 26 Oct 2022, Accepted 20 Feb 2023, Published online: 09 Mar 2023

References

  • Herzberg J, Fischer B, Becher H, et al. Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine – a prospective observational study. Front Immunol. 2022;13:1–9.
  • Liu X, Munro APS, Feng S, et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. J Infect. 2022;84:795–813.
  • Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection. JAMA Netw Open. 2022;5:e2231778.
  • Maringer Y, Nelde A, Schroeder SM, et al. Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci Immunol. 2022;7:eadd3899.
  • Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA. 2022;327:639.
  • Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (omicron) depends on previous SARS-CoV-2 exposure. Science (80-). 2022;377:eabq1841.
  • GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7:eabo2202.
  • Wang X, Zhao X, Song J, et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 omicron variant escape from neutralizing antibodies. Emerg Microbes Infect. 2022;11:477.
  • Miyamoto S, Arashiro T, Adachi Y, et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 omicron after breakthrough infection by other variants. Med. 2022;3:249–261.e4.
  • Tré-Hardy M, Cupaiolo R, Wilmet A, et al. Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected. J Infect. 2022;84:e31–e33.
  • Munro APSS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276.
  • Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous COVID-19 booster vaccinations. N Engl J Med. 2022;386:1046–1057.
  • Behrens GMN, Barros-Martins J, Cossmann A, et al. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nat Commun. 2022;13:1–10.
  • Jacobsen H, Cobos Jiménez V, Sitaras I, et al. Post-vaccination T cell immunity to omicron. Front Immunol. 2022;13:1–8.
  • Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. Nat Rev Immunol. 2022;22:7–18.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.